Showing results (401-410 of 974) with videos related to

Sort By:
Pageof 98
Cancer Immunology, Immunotherapy : CII|January 27, 2026
Metabolic syndrome and immune-related adverse eventsKatherine Lei, Meera J Patel, Jialiang Liu, et al.
Population Health Management|May 23, 2023
Assessing Barriers and Facilitators to Lung Cancer Screening: Initial Findings from a Patient Navigation InterventionSimon J Craddock Lee, Jessica Lee, Hong Zhu, et al.
Scientific Reports|November 26, 2015
Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachoneGaurab Chakrabarti, Molly A Silvers, Mariya Ilcheva, et al.
Translational Lung Cancer Research|December 10, 2025
Association of PD-L1 expression with systemic immune parameters in non-small cell lung cancerMary E Gwin, Mitchell S von Itzstein, Jialiang Liu, et al.
Journal for Immunotherapy of Cancer|January 6, 2025
Novel and potent MICA/B antibody is therapeutically effective in <i>KRAS LKB1</i> mutant lung cancer modelsRyan R Kowash, Manoj Sabnani, Laura T Gray, et al.
Eclinicalmedicine|October 7, 2025
Osimertinib plus consolidative radiotherapy for advanced <i>EGFR</i> mutant non-small cell lung cancer: a multicentre, single-arm, phase 2 trialSagus Sampath, Sawsan Rashdan, Puneeth Iyengar, et al.
The Oncologist|June 9, 2017
A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRASChristopher H Lieu, Manuel Hidalgo, Jordan D Berlin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2011
Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancerLecia V Sequist, Joachim von Pawel, Edward G Garmey, et al.
Contemporary Clinical Trials|September 12, 2022
Enhancing access to and diversity in cancer clinical trials through a financial reimbursement program: Protocol to evaluate a novel programDavid E Gerber, Jasmin A Tiro, Lorna H McNeill, et al.
Contemporary Clinical Trials Communications|April 16, 2024
Transferring care to enhance access to early-phase cancer clinical trials: Protocol to evaluate a novel programChika Nwachukwu, Sukh Makhnoon, Marieshia Person, et al.
Pageof 98